Hansoh Pharmaceutical Group CoHNSPF 90 PEG Ratio is 2.25 as of Jul. 04, 2026, which is 29% below its 10-year median of 3.19. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.63 (Fairly Valued). Among 349 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks worse than 61.03% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's PEG Ratio or its related term are showing as below:
HNSPF'
s PEG Ratio Range Over the Past 10 Years
Min: 1.44 Med: 3.19 Max: 8.21
Current: 2.53
During the past 10 years, Hansoh Pharmaceutical Group Co's highest PEG Ratio was 8.21. The lowest was 1.44. And the median was 3.19.
HNSPF's PEG Ratio is ranked worse than 61.03% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs HNSPF: 2.53
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Hansoh Pharmaceutical Group Co PEG Ratio Related Terms
Hansoh Pharmaceutical Group Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Hansoh Pharmaceutical Group Co (HNSPF) has a PEG Ratio of 2.25 as of Jul. 04, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 29% below median its historical median of 3.19. Over the past decade, Hansoh Pharmaceutical Group Co's PEG Ratio has ranged from 1.44 to 8.21. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #213 out of 349 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is Hansoh Pharmaceutical Group Co's PEG Ratio too high?
Hansoh Pharmaceutical Group Co's current PEG Ratio of 2.25 is 29% below median its 10-year median of 3.19. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 8.21. The Drug Manufacturers industry median PEG Ratio is 1.71. Hansoh Pharmaceutical Group Co's value of 2.25 is 31.6% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #213 out of 349 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #213 out of 349 companies for PEG Ratio. This places Hansoh Pharmaceutical Group Co in the lower half of its industry. The industry median PEG Ratio is 1.71. Hansoh Pharmaceutical Group Co's value of 2.25 is 31.6% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own PEG Ratio has ranged from 1.44 to 8.21 over the past decade. While the company's 10-year median is 3.19 vs. the industry median of 1.71, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current PEG Ratio of 2.25 is 31.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current PEG Ratio is 2.25, which is 29% below median its own 10-year median of 3.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Fairly Valued. The stock's GF Value™ is $3.63, compared to a current price of $3.83 — trading 5.4% above its estimated fair value. The current PEG Ratio is 2.25, which is 29% below median its 10-year median of 3.19 and 31.6% above the Drug Manufacturers industry median of 1.71. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current PEG Ratio is 2.25 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 5.4% above its estimated GF Value™ of $3.63.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for HNSPF:
PEG Ratio: 2.25 (29% below median its 10-year median of 3.19)
GF Value™: $3.63 vs. price of $3.83 (5.4% above fair value)
Industry Position: 31.6% above the Drug Manufacturers median (#213 of 349)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score
Get the complete analysis for HNSPF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
